Study details
Enrolling now
Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
Robert Nickel
NCT IDNCT03587272ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
100
Study length
about 13 years
Ages
2–25
Locations
5 sites in DC, IL, NC +2
What this study is about
This trial is testing a new way to transplant bone marrow from an identical sibling donor into children with sickle cell disease. The goal is to reduce the side effects of this treatment while still achieving a high success rate.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Alemtuzumab, low dose total body irradiation, Sirolimus
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IVInjection / IV
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
alemtuzumab, sirolimus
Drug routes
injection (Injection), injection, intravenous
Endpoints
Secondary: PedsQL 4.0 Measurement model for the Pediatric Quality of Life Inventory